MI
$0.78
-0.03
(-3.74%)
As of Oct 5, 2026, 5:11 PM EDT
Price history
Milestone Pharmaceuticals (MIST) is trading down at $0.78 (-3.74%), as of the latest quote. It operates in the Health Care sector.
IPO: May 9, 2019 · $15.00 offering · NASDAQ · View IPO details →
Milestone Pharmaceuticals net income history (FY2018–FY2025)
Net income
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$23.8M | −$57.9M | −$50.7M | −$43.1M | −$59.6M | −$61.1M | −$42.1M | −$62.1M |
| Net income | −$23.2M | −$55.2M | −$50.0M | −$42.9M | −$58.4M | −$59.7M | −$41.5M | −$63.1M |
| EPS (diluted) | $72.63 | −$3.50 | −$1.70 | −$1.02 | −$1.38 | −$1.39 | −$0.67 | −$0.75 |
| Balance sheet | ||||||||
| Cash and equivalents | $85.9M | $119.8M | $72.3M | $114.1M | $7.64M | $13.8M | $25.3M | $73.0M |
| Total assets | $88.1M | $123.4M | $150.0M | $119.8M | $74.5M | $75.2M | $75.5M | $113.6M |
| Total liabilities | $4.53M | $8.51M | $6.86M | $7.25M | $8.13M | $58.5M | $62.4M | $71.8M |
| Long-term debt | — | $0 | — | — | — | $49.8M | $53.4M | $57.2M |
| Shareholders' equity | $83.5M | $114.9M | $143.1M | $112.6M | $66.3M | $16.8M | $13.1M | $41.8M |
| Cash flow | ||||||||
| Operating cash flow | −$21.0M | −$51.2M | −$50.7M | −$33.2M | −$52.5M | −$46.4M | −$28.8M | −$49.0M |
| Capital expenditure | $5.00K | $413.0K | — | — | $272.0K | $112.0K | $33.0K | $302.0K |
| Free cash flow | −$21.1M | −$51.6M | — | — | −$52.7M | −$46.5M | −$28.9M | −$49.3M |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | $0 | $0 | — | — | $238.0K | $559.0K |
| Gross profit | — | — | $0 | $0 | — | — | $224.0K | $527.0K |
| Gross margin | — | — | — | — | — | — | 94.1% | 94.3% |
| Operating income | −$9.62M | −$12.3M | −$20.5M | −$12.5M | −$11.8M | −$17.3M | −$23.7M | −$25.6M |
| Operating margin | — | — | — | — | — | — | −9942.4% | −4585.0% |
| Net income | −$9.44M | −$12.4M | −$20.8M | −$13.0M | −$11.9M | −$17.4M | −$26.1M | −$28.6M |
| Net margin | — | — | — | — | — | — | −10952.1% | −5118.8% |
| EPS (diluted) | −$0.14 | −$0.18 | −$0.31 | −$0.20 | −$0.12 | −$0.12 | −$0.20 | −$0.21 |
| Balance sheet | ||||||||
| Cash and equivalents | $12.8M | $25.3M | $45.1M | $42.5M | $46.7M | $73.0M | $71.3M | $169.7M |
| Total assets | $82.7M | $75.5M | $61.9M | $47.4M | $87.8M | $113.6M | $193.7M | $181.6M |
| Total liabilities | $58.7M | $62.4M | $68.0M | $65.2M | $67.2M | $71.8M | $157.7M | $163.4M |
| Long-term debt | $52.4M | $53.4M | $54.3M | $55.2M | $56.2M | $57.2M | $58.2M | $59.2M |
| Shareholders' equity | $24.0M | $13.1M | −$6.12M | −$17.7M | $20.5M | $41.8M | $36.0M | $18.2M |
| Cash flow | ||||||||
| Operating cash flow | −$7.02M | −$6.84M | −$14.0M | −$12.6M | −$9.75M | −$12.8M | −$16.1M | −$22.7M |
| Capital expenditure | $4.00K | $22.0K | $6.00K | $11.0K | $2.00K | $283.0K | $45.0K | $26.0K |
| Free cash flow | −$7.02M | −$6.87M | −$14.0M | −$12.6M | −$9.75M | −$13.1M | −$16.1M | −$22.7M |
From Milestone Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Milestone Pharmaceuticals
- Headquarters
- Montreal, Canada From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with MIST
- MGNX MacroGenics
- MGTX Meiragtx Holdings PLC
- MGX Metagenomi Therapeutics
- MIRM Mirum Pharmaceuticals Inc
- MLAB Mesa Laboratories Inc
- MLYS Mineralys Therapeutics Inc
- MMED MiniMed Group
- MMSI Merit Medical Systems Inc